East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Carbidopa Tablets, 25 mg.  Aurobindo’s Carbidopa Tablets, 25 mg are an AB-rated generic equivalent to the reference listed drug, Bausch Health Americas, Inc.’s Lodosyn® Tablets, 25mg.

Carbidopa Tablets are indicated for use with carbidopa-levodopa or with levodopa in the treatment of the symptoms of idiopathic Parkinson’s disease (paralysis agitans), postencephalitic parkinsonism, and symptomatic park which may follow injury to the nervous system by carbon monoxide intoxication and/or manganese intoxication.

Carbidopa Tablets has an estimated market size of US $7.7 Million for the twelve months ending August 2019 as per IQVIA.

* IMS National Sales Perspectives: Retail and Non-Retail MAT August 2019